{"text": "The dosing recommendation is applicable to the recommended dose of EDURANT 25 mg once daily .Rilpivirine did not have a clinically significant effect on the pharmacokinetics of digoxin or metformin .", "label": "", "metadata": {}, "score": "28.4962"}
{"text": "This observation was the same in the efavirenz arm .The pharmacokinetic exposure of rilpivirine in co - infected subjects was comparable to that in subjects without co - infection .", "label": "", "metadata": {}, "score": "28.948288"}
{"text": "More subjects treated with rilpivirine developed tenofovir and lamivudine / emtricitabine associated resistance compared to efavirenz [ See Microbiology ] .The following points should be met when considering replacing the current regimen with COMPLERA in virologically - suppressed adults [ See Clinical Studies ] : .", "label": "", "metadata": {}, "score": "29.615654"}
{"text": "The combination of EDURANT and H2-receptor antagonists should be used with caution as coadministration may cause significant decreases in rilpivirine plasma concentrations ( increase in gastric pH ) .", "label": "", "metadata": {}, "score": "31.504692"}
{"text": "Concomitant use of EDURANT with azole antifungal agents may cause an increase in the plasma concentrations of rilpivirine ( inhibition of CYP3A enzymes ) .No rilpivirine dose adjustment is required when EDURANT is co - administered with azole antifungal agents .", "label": "", "metadata": {}, "score": "31.713528"}
{"text": "He suggested finding a treatment combination that would be equally effective without the side effects of Atripla ( these would not be a single pill ) .", "label": "", "metadata": {}, "score": "31.870224"}
{"text": "US clinical researchers mounted this trial to assess the viability of switching from Atripla to Complera , which combines the nonnucleoside rilpivirine with tenofovir / emtricitabine in a single once - daily tablet .", "label": "", "metadata": {}, "score": "31.908615"}
{"text": "Co- administration of EDURANT and drugs that induce CYP3A may result in decreased plasma concentrations of rilpivirine and loss of virologic response and possible resistance to rilpivirine or to the class of NNRTIs .", "label": "", "metadata": {}, "score": "31.965313"}
{"text": "But switching from efavirenz to rilpivirine lowered rilpivirine trough concentrations about 25 % in a study of healthy volunteers [ 5].Study participants took Atripla as their first regimen and continued treatment for at least 3 months .", "label": "", "metadata": {}, "score": "32.93174"}
{"text": "More subjects treated with EDURANT developed tenofovir and lamivudine / emtricitabine associated resistance compared to efavirenz .5.3 Hepatotoxicity .Hepatic adverse events have been reported in patients receiving a rilpivirine containing regimen .", "label": "", "metadata": {}, "score": "34.118507"}
{"text": "For others , depending on frequency and character of side effects , the quality of life can be adversely impacted so a trial switch to an alternative regime is worth considering .", "label": "", "metadata": {}, "score": "34.464645"}
{"text": "No dose adjustment is required when EDURANT is co - administered with darunavir / ritonavir .Concomitant use of EDURANT with lopinavir / ritonavir may cause an increase in the plasma concentrations of rilpivirine ( inhibition of CYP3A enzymes ) .", "label": "", "metadata": {}, "score": "34.82238"}
{"text": "Patients should currently be on their first or second antiretroviral regimen prior to switching therapy .Patients should have no current or past history of resistance to any of the three components of COMPLERA .", "label": "", "metadata": {}, "score": "35.310776"}
{"text": "Study to Evaluate Switching From Regimens Consisting of a Ritonavir - boosted Protease Inhibitor ( PI ) and Two Nucleoside Reverse Transcriptase Inhibitors ( NRTIs ) to a Fixed - dose Tablet Containing Emtricitabine / Rilpivirine / Tenofovir DF .", "label": "", "metadata": {}, "score": "35.56173"}
{"text": "Effect on Concentration of Rilpivirine or Concomitant Drug .Clinical Comment .HIV - Antiviral Agents : Nucleoside Reverse Transcriptase Inhibitors ( NRTIs ) .No dose adjustment is required when EDURANT is co - administered with didanosine .", "label": "", "metadata": {}, "score": "36.382168"}
{"text": "The findings indicated that although \" both drugs suffered from missed doses , \" rilpivirine did not appear to do worse .Lipid Improvements .Pablo Tebas from the University of Pennsylvania reported findings from the phase 3 SPIRIT study , which looked at outcomes among people with suppressed viral load who simplified treatment by switching from a ritonavir - boosted protease inhibitor plus 2 nucleoside / nucleotide reverse transcriptase inhibitors ( NRTIs ) to Complera .", "label": "", "metadata": {}, "score": "36.619263"}
{"text": "INDICATIONS .The following points should be considered when initiating therapy with COMPLERA in adult patients with no antiretroviral treatment history : .Regardless of HIV-1 RNA level at the start of therapy , more rilpivirine - treated subjects with CD4 + cell count less than 200 cells / mm3 experienced virologic failure compared to rilpivirine - treated subjects with CD4 + cell count greater than or equal to 200 cells / mm3 [ See Clinical Studies ] .", "label": "", "metadata": {}, "score": "36.903393"}
{"text": "Rilpivirine is available as a free - standing agent and as a component in a fixed - dose combination with tenofovir / emtricitabine ( Complera ) .", "label": "", "metadata": {}, "score": "37.001442"}
{"text": "No dose adjustments are required when initiating co - administration of methadone with EDURANT .However , clinical monitoring is recommended as methadone maintenance therapy may need to be adjusted in some patients .", "label": "", "metadata": {}, "score": "38.047012"}
{"text": "Nephrotic syndrome was added to the postmarketing experience subsection .Section 7 Drug Interactions troleandomycin was removed from the table 7 .Telithromycin was added with the clinical comment that telithromycin may cause an increase increase in the plasma concentrations of rilpivirine ( inhibition of CYP3A enzymes ) .", "label": "", "metadata": {}, "score": "38.091522"}
{"text": "Persons taking raltegravir who experience rash or symptoms of hypersensitivity should be evaluated promptly , and raltegravir should be discontinued if it is thought to be a contributing factor .", "label": "", "metadata": {}, "score": "38.255043"}
{"text": "Concomitant use of EDURANT with rifabutin may cause a decrease in the plasma concentrations of rilpivirine ( induction of CYP3A enzymes ) .Throughout co - administration of EDURANT with rifabutin , the EDURANT dose should be increased from 25 mg once daily to 50 mg once daily .", "label": "", "metadata": {}, "score": "38.572556"}
{"text": "These changes are not considered to be clinically relevant and no subject discontinued treatment due to increases in serum creatinine .Serum creatinine increases occurred regardless of the background N(t)RTI regimen .", "label": "", "metadata": {}, "score": "38.782383"}
{"text": "A few cases of hepatic toxicity have been reported in patients receiving a rilpivirine containing regimen who had no pre - existing hepatic disease or other identifiable risk factors .", "label": "", "metadata": {}, "score": "38.941475"}
{"text": "Section 12.4 Microbiology was updated with the Week 96 data .The following new paragraph was added to this section .This difference was also observed for the individual emtricitabine / lamivudine and tenofovir resistance substitutions : 23 % ( 11/47 ) compared to 77 % ( 36/47 ) for M184I / V and 0 % ( 0/8 ) compared to 100 % ( 8/8 ) for K65R / N. Section 14 Clinical Studies was updated as follows : .", "label": "", "metadata": {}, "score": "39.465813"}
{"text": "Two years of Atripla with persistent possible efavirenz side effects merits consideration of a trial switch ( ? to alternative NNRTI such as nevirapine or rilpivirine , to a boosted PI such as atazanavir or darunavir , to raltegravir , possibly to maraviroc , or even to an investigational regimen if studies are available --such as the QUAD pill ) .", "label": "", "metadata": {}, "score": "39.55102"}
{"text": "Because COMPLERA is a fixed - dose combination , it should not be prescribed for patients requiring dose reduction such as those with moderate or severe renal impairment ( estimated creatinine clearance below 50 mL per minute ) .", "label": "", "metadata": {}, "score": "40.048653"}
{"text": "Macrolide or ketolide antibiotics : clarithromycin erythromycin telithromycin .Concomitant use of EDURANT with clarithromycin , erythromycin or telithromycin may cause an increase in the plasma concentrations of rilpivirine ( inhibition of CYP3A enzymes ) .", "label": "", "metadata": {}, "score": "40.70215"}
{"text": "References .Mills A , Cohen C , Dejesus E , et al .Switching from efavirenz / emtricitabine / tenofovir disoproxil fumarate ( EFV / FTC / TDF ) single tablet regimen ( STR ) to emtricitabine / rilpivirine / tenofovir disoproxil fumarate ( FTC / RPV / TDF ) STR in virologically suppressed , HIV-1 infected subjects .", "label": "", "metadata": {}, "score": "41.013355"}
{"text": "October 2 - 6 , 2013 .Abstract 671 .P Tebas , F Palella , P Ruane , et al .SPIRIT : simplification to rilpivirine / emtricitabine / tenofovir DF single - tablet regimen from boosted protease inhibitor maintains HIV-1 suppression and improves fasting lipids at week 48 . 2nd IDWeek Conference ( IDWeek 2013 ) .", "label": "", "metadata": {}, "score": "41.175995"}
{"text": "Below is a summary of the recent changes .Indications and Usage .EDURANT , in combination with other antiretroviral agents , is indicated for the treatment of human immunodeficiency virus type 1 ( HIV\u20111 ) infection in antiretroviral treatment\u2011na\u00efve adult patients with HIV-1 RNA less than or equal to 100,000 copies / mL at the start of therapy .", "label": "", "metadata": {}, "score": "41.43615"}
{"text": "Significant events and approaches for the overall study following participant enrollment , but prior to group assignment .617 participants were screened .Participants were randomized to switch from their existing treatment regimen to the emtricitabine ( FTC)/rilpivirine ( RPV)/tenofovir disoproxil fumarate ( TDF ) single - tablet regimen ( STR ) at the beginning of the study .", "label": "", "metadata": {}, "score": "42.046165"}
{"text": "Significant events and approaches for the overall study following participant enrollment , but prior to group assignment .617 participants were screened .Participants were randomized to switch from their existing treatment regimen to the emtricitabine ( FTC)/rilpivirine ( RPV)/tenofovir disoproxil fumarate ( TDF ) single - tablet regimen ( STR ) at the beginning of the study .", "label": "", "metadata": {}, "score": "42.046165"}
{"text": "Because clinical trials are conducted under widely varying conditions , adverse reaction rates observed in the clinical trials of a drug can not be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice .", "label": "", "metadata": {}, "score": "43.435173"}
{"text": "Dosage Forms And Strengths .COMPLERA is available as tablets .Each tablet contains 200 mg of emtricitabine ( FTC ) , 27.5 mg of rilpivirine hydrochloride ( equivalent to 25 mg of rilpivirine ) and 300 mg of tenofovir disoproxil fumarate ( tenofovir DF or TDF , equivalent to 245 mg of tenofovir disoproxil ) .", "label": "", "metadata": {}, "score": "43.441765"}
{"text": "EDURANT is not expected to affect the plasma concentrations of co - administered PIs .Concomitant use of EDURANT with unboosted PIs may cause an increase in the plasma concentrations of rilpivirine ( inhibition of CYP3A enzymes ) .", "label": "", "metadata": {}, "score": "43.473267"}
{"text": "Rilpivirine Added to DHHS Recommendations .Recommendations for use of the recently approved NNRTI rilpivirine have been added to the U.S. Department of Health and Human Services adult and adolescent ART guidelines .", "label": "", "metadata": {}, "score": "43.479515"}
{"text": "If COMPLERA is coadministered with rifabutin , an additional 25 mg tablet of rilpivirine ( Edurant \u00ae ) once per day is recommended to be taken concomitantly with COMPLERA and with a meal for the duration of the rifabutin coadministration [ See DRUG INTERACTIONS and CLINICAL PHARMACOLOGY ] .", "label": "", "metadata": {}, "score": "44.42588"}
{"text": "An oral suspension formulation of darunavir ( 100 mg / mL ) has been approved by the U.S. Food and Drug Administration .Dosage recommendations for children 3 - 6 years of age are forthcoming .", "label": "", "metadata": {}, "score": "44.455086"}
{"text": "Participants were randomized to switch from their existing treatment regimen to the FTC / RPV / TDF STR at the beginning of the study .SBR / Delayed Switch .", "label": "", "metadata": {}, "score": "44.647446"}
{"text": "References .C Cohen , D Wohl , K Henry , et al .STaR study : association of efficacy outcomes with baseline HIV-1 RNA and CD4 count and adherence rate for the single - tablet regimens rilpivirine / emtricitabine / tenofovir DF and efavirenz / emtricitabine / tenofovir DF in ART - naive adults . 2nd IDWeek Conference ( IDWeek 2013 ) .", "label": "", "metadata": {}, "score": "45.234444"}
{"text": "February 27-March 2 , 2011 .Boston .Abstract 630 .Study to Evaluate Switching From Regimens Consisting of a Ritonavir - boosted Protease Inhibitor ( PI ) and Two Nucleoside Reverse Transcriptase Inhibitors ( NRTIs ) to a Fixed - dose Tablet Containing Emtricitabine / Rilpivirine / Tenofovir DF .", "label": "", "metadata": {}, "score": "45.397175"}
{"text": "Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment - naive adults infected with HIV-1 ( THRIVE ) : a phase 3 , randomised , non - inferiority trial .", "label": "", "metadata": {}, "score": "46.449604"}
{"text": "Participants were randomly assigned to switch to Complera either immediately or after 6 months .Tebas ' report focused on changes in blood lipids , which are known to affect cardiovascular risk .", "label": "", "metadata": {}, "score": "46.9664"}
{"text": "Four grade 1 or 2 treatment - emergent events affected 2 people , both with nausea and insomnia .Serum creatinine rose by an average 0.11 mg / dL at week 12 from 0.97 mg / dL at study entry .", "label": "", "metadata": {}, "score": "47.165424"}
{"text": "DOSAGE AND ADMINISTRATION .Adults .The recommended dose of COMPLERA is one tablet taken orally once daily with food [ See CLINICAL PHARMACOLOGY ] .", "label": "", "metadata": {}, "score": "47.489838"}
{"text": "Selected treatment - emergent laboratory abnormalities are included in Table 2 .Insomnia .Abnormal dreams .Skin and Subcutaneous Tissue Disorders .Rash .No new ADR terms were identified in adult subjects in the Phase 3 TMC278-C209 and TMC278-C215 trials between 48 weeks and 96 weeks nor in the Phase 2b TMC278-C204 trial through 240 weeks .", "label": "", "metadata": {}, "score": "48.03679"}
{"text": "Adverse reactions have been identified during postmarketing experience in patients receiving a rilpivirine containing regimen .Because these reactions are reported voluntarily from a population of unknown size , it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure .", "label": "", "metadata": {}, "score": "48.066612"}
{"text": "People with at least 95 % adherence reported better tolerability on both regimens .In particular , highly adherent patients taking Atripla reported fewer efavirenz - associated central nervous system ( CNS ) side effects such as abnormal dreams or depression .", "label": "", "metadata": {}, "score": "48.362522"}
{"text": "\" Those who switch their HIV regimen to Complera should never have experienced virologic failure , have at least six months of an undetectable viral load , and never have had resistance to the drugs in Complera .", "label": "", "metadata": {}, "score": "48.665367"}
{"text": "Among people with the least favorable combination -- high viral load , low CD4 count , and sub - optimal adherence -- only 50 % achieved viral suppression with either single - tablet regimen .", "label": "", "metadata": {}, "score": "48.774776"}
{"text": "All 49 study participants maintained a viral load below 50 copies for 12 weeks after switching to Complera .Rilpivirine trough concentrations in the phase 3 rilpivirine trials lay between 50 and 80 ng / mL. In the current study rilpivirine troughs reached the target range within 2 weeks of dosing , averaging 52 ng / mL ( coefficient of variation 47 % ) 2 weeks after the switch .", "label": "", "metadata": {}, "score": "48.896492"}
{"text": "- administration of EDURANT and drugs that inhibit CYP3A may result in increased plasma concentrations of rilpivirine .Co- administration of EDURANT with drugs that increase gastric pH may result in decreased plasma concentrations of rilpivirine and loss of virologic response and possible resistance to rilpivirine or to the class of NNRTIs .", "label": "", "metadata": {}, "score": "49.030914"}
{"text": "Molina JM , Cahn P , Grinsztejn B , et al ; ECHO study group .Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment - naive adults infected with HIV-1 ( ECHO ) : a phase 3 randomised double - blind active - controlled trial .", "label": "", "metadata": {}, "score": "49.041145"}
{"text": "Additionally , it requires gastric acid for absorption and can not be given with proton - pump inhibitors ( dosing of other acid - lowering medications requires specific timing ) .", "label": "", "metadata": {}, "score": "49.635757"}
{"text": "EDURANT should be used with caution when co - administered with a drug with a known risk of Torsade de Pointes .Complera . \"Infants exposed in the womb to a drug used to treat HIV and reduce the transmission of HIV from mother to child , may have lower bone mineral content than those exposed to other anti - HIV drugs , according to a National Institutes of Health study \" ... .", "label": "", "metadata": {}, "score": "50.000313"}
{"text": "October 2 - 6 , 2013 .Abstract 672 .The U.S. Food and Drug Administration ( FDA ) has approved Gilead Sciences ' coformulated triple antiretroviral ( ARV ) combination tablet Complera ( emtricitabine / rilpivirine / tenofovir ) for those HIV - positive adults who switch from a stable ARV regimen .", "label": "", "metadata": {}, "score": "50.113255"}
{"text": "In the pooled Phase 3 trials , an increase in serum creatinine was observed over the 96 weeks of treatment with EDURANT .Most of this increase occurred within the first four weeks of treatment , with a mean change of 0.1 mg / dL ( range : -0.3 mg / dL to 0.6 mg / dL ) observed after 96 weeks of treatment .", "label": "", "metadata": {}, "score": "51.169067"}
{"text": "Another study found that switching from a boosted protease inhibitor to Complera lowered cholesterol and triglyceride levels .Calvin Cohen from the Community Research Initiative of New England reported findings from the open - label STaR trial , the first head - to - head comparison of Complera vs Atripla in people starting antiretroviral therapy ( ART ) for the first time .", "label": "", "metadata": {}, "score": "51.27948"}
{"text": "Less Common Adverse Drug Reactions .Some adverse events have been included because of investigator 's assessment of potential causal relationship and were considered serious or have been reported in more than 1 subject treated with EDURANT .", "label": "", "metadata": {}, "score": "51.96423"}
{"text": "Labeling Updates for Edurant ( Rilpivirine ) .On December 7 , 2012 , FDA approved changes to the Edurant ( rilpivirine ) package insert .", "label": "", "metadata": {}, "score": "51.996502"}
{"text": "These changes resulted in overall improvement in lipid profiles after switching to Complera .At baseline , 59 % of participants were classified as having NCEP desirable total cholesterol levels ; at 24 weeks , this rose to 84 % in the immediate switch group while remaining about the same for people who remained on protease inhibitors .", "label": "", "metadata": {}, "score": "52.66519"}
{"text": "Interscience Conference on Antimicrobial Agents and Chemotherapy ( ICAAC ) , September 17 - 20 , 2011 , Chicago .Mark Mascolini .Switching from the first one - pill once - daily antiretroviral regimen , Atripla , to the second , Complera , kept viral loads in check and caused no safety or tolerability problems through 12 weeks of follow - up in a 49-person single - arm trial [ 1].", "label": "", "metadata": {}, "score": "52.668015"}
{"text": "The percentage of subjects treated with EDURANT or efavirenz in the Phase 3 trials with selected treatment - emergent clinical laboratory abnormalities ( Grades 1 to 4 ) , representing worst Grade toxicity are shown in Table 2 .", "label": "", "metadata": {}, "score": "53.01935"}
{"text": "Changes from baseline in total cholesterol , LDL - cholesterol , HDL -cholesterol and triglycerides are presented in Table 3 .The clinical benefit of these findings has not been demonstrated .", "label": "", "metadata": {}, "score": "53.36802"}
{"text": "From weeks 4 to 12 rilpivirine troughs averaged 66 to 84 ng / mL. Rilpivirine concentrations never fell below the detection limit at any study visit .", "label": "", "metadata": {}, "score": "53.554893"}
{"text": "Safety Analysis Set : participants who were randomized and received at least one dose of study drug .Reporting Groups .Description .FTC / RPV / TDF .", "label": "", "metadata": {}, "score": "53.777126"}
{"text": "Safety Analysis Set : participants who were randomized and received at least one dose of study drug .Reporting Groups .Description .FTC / RPV / TDF .", "label": "", "metadata": {}, "score": "53.777126"}
{"text": "Pooled Data from the Week 96 Analysis of the Phase 3 TMC278-C209 and TMC278-C215 Trials .Triglycerides ( fasted ) .Subjects Co - Infected With Hepatitis B And / Or Hepatitis C Virus .", "label": "", "metadata": {}, "score": "53.784153"}
{"text": "The following points should be considered when initiating therapy with EDURANT : .Regardless of HIV-1 RNA at the start of therapy , more EDURANT treated subjects with CD4 + cell count less than 200 cells / mm 3 experienced virologic failure compared to EDURANT treated subjects with CD4 + cell count greater than or equal to 200 cells / mm 3 .", "label": "", "metadata": {}, "score": "53.87243"}
{"text": "QT Prolonging Drugs .There is limited information available on the potential for a pharmacodynamic interaction between rilpivirine and drugs that prolong the QTc interval of the electrocardiogram .", "label": "", "metadata": {}, "score": "54.126728"}
{"text": "SBR / Delayed Switch .Participants were randomized to stay on their existing treatment regimen ( Stay on Baseline Regimen ( SBR ) ) at the beginning of the study through Week 24 , and switch to the FTC / RPV / TDF STR ( Delayed Switch ) at the Week 24 visit .", "label": "", "metadata": {}, "score": "54.19005"}
{"text": "SBR / Delayed Switch .Participants were randomized to stay on their existing treatment regimen ( Stay on Baseline Regimen ( SBR ) ) at the beginning of the study through Week 24 , and switch to the FTC / RPV / TDF STR ( Delayed Switch ) at the Week 24 visit .", "label": "", "metadata": {}, "score": "54.19005"}
{"text": "Most ADRs occurred in the first 48 weeks of treatment .The proportion of subjects who discontinued treatment with EDURANT or efavirenz due to ADR , regardless of severity , was 2 % and 4 % , respectively .", "label": "", "metadata": {}, "score": "54.204956"}
{"text": "Non - TDF - containing regimen + LPV / RTV .Non - TDF - containing regimen + Other PI+RTV .[ 1 ] .Four participants in the Switch to FTC / RPV / TDF group and 2 participants in the Stay on Baseline Regimen ( SBR ) group were randomized but were not treated .", "label": "", "metadata": {}, "score": "54.555866"}
{"text": "Non - TDF - containing regimen + LPV / RTV .Non - TDF - containing regimen + Other PI+RTV .[ 1 ] .Four participants in the Switch to FTC / RPV / TDF group and 2 participants in the Stay on Baseline Regimen ( SBR ) group were randomized but were not treated .", "label": "", "metadata": {}, "score": "54.555866"}
{"text": "Results .At 48 weeks , 89 % in the immediate switch arm still had undetectable viral load .Total cholesterol levels fell by -25 mg / dL following either an immediate or delayed switch to Complera , while LDL \" bad \" cholesterol fell by about -16 mg / dL. HDL \" good \" cholesterol fell by only a small amount ( -2 to -4 mg / dL ) .", "label": "", "metadata": {}, "score": "54.764397"}
{"text": "After 48 weeks of Complera , 89 percent ( 283/317 ) of the participants in the switching arm had a fully suppressed viral load , compared with 90 percent ( 143/159 ) of those in the protease inhibitor arm , who were followed for 24 weeks .", "label": "", "metadata": {}, "score": "55.388252"}
{"text": "HIV - Antiviral Agents : Non - nucleoside Reverse Transcriptase Inhibitors ( NNRTIs ) .NNRTI ( delavirdine )Other NNRTIs ( efavirenz , etravirine , nevirapine ) .", "label": "", "metadata": {}, "score": "55.51922"}
{"text": "Rash led to discontinuation in 1 ( 0.1 % ) subject in the EDURANT arm and 10 ( 1.5 % ) subjects in the efavirenz arm .", "label": "", "metadata": {}, "score": "55.793385"}
{"text": "Crauwels H , Vingerhoets J , Ryan R , Witek J , Anderson D. Pharmacokinetic parameters of once - daily TMC278 following administration of EFV in healthy volunteers . 18th", "label": "", "metadata": {}, "score": "57.04327"}
{"text": "\"No adverse events forced participants to drop out of the trial .Two grade 2 drug - related events , fatigue and increased bilirubin , arose .", "label": "", "metadata": {}, "score": "57.378605"}
{"text": "Participants were randomized to stay on their existing treatment regimen ( Stay on Baseline Regimen ( SBR ) ) at the beginning of the study through Week 24 , and switch to the FTC / RPV / TDF STR ( Delayed Switch ) at the Week 24 visit .", "label": "", "metadata": {}, "score": "57.85417"}
{"text": "Participants were randomized to stay on their existing treatment regimen ( Stay on Baseline Regimen ( SBR ) ) at the beginning of the study through Week 24 , and switch to the FTC / RPV / TDF STR ( Delayed Switch ) at the Week 24 visit .", "label": "", "metadata": {}, "score": "57.85417"}
{"text": "HIV - Antiviral Agents : Protease Inhibitors ( PIs)-Boosted ( i.e. , with co - administration of low - dose ritonavir ) or Unboosted ( i.e. , without co - administration of low - dose ritonavir ) .", "label": "", "metadata": {}, "score": "57.88258"}
{"text": "Triglyceride levels in the immediate switch arm fell by -54 mg / dL at 24 weeks and by -65 mg / dL at 48 weeks ; the delayed switch arm saw a -81 mg / dL drop .", "label": "", "metadata": {}, "score": "58.242107"}
{"text": "Table 4 : Established and Other Potentially Significant Drug Interactions : Alterations in Dose or Regimen May Be Recommended Based on Drug Interaction Studies or Predicted Interaction [ see CLINICAL PHARMACOLOGY ] .", "label": "", "metadata": {}, "score": "58.77488"}
{"text": "At baseline about one - third each were taking boosted atazanavir ( Reyataz ) and lopinavir / ritonavir ( Kaletra ) , while 20 % were on boosted darunavir ( Prezista ) .", "label": "", "metadata": {}, "score": "59.727882"}
{"text": "The proportion of people with optimal LDL rose after the switch to Complera ( from 29 % to 45 % ) , while the percentage with high HDL fell a bit ( from 27 % to 17 % ) .", "label": "", "metadata": {}, "score": "60.216618"}
{"text": "Mean values for both basal and ACTH - stimulated cortisol values at Week 96 were within the normal range .Overall , there were no serious adverse events , deaths , or treatment discontinuations that could clearly be attributed to adrenal insufficiency .", "label": "", "metadata": {}, "score": "63.05465"}
{"text": "Table 4 shows the established and other potentially significant drug interactions based on which alterations in dose or regimen of EDURANT and/or co - administered drug may be recommended .", "label": "", "metadata": {}, "score": "63.165127"}
{"text": "Response rates dropped among people with less than 95 % adherence , to 75 % and 66 % , respectively , but neither difference between the 2 regimens was significant .", "label": "", "metadata": {}, "score": "63.249706"}
{"text": "Comments require captcha .Side Effects : How mild is mild ?but my new HIV Doctor has questioned this by saying my long - term goal should be treatment with zero side effects .", "label": "", "metadata": {}, "score": "63.25853"}
{"text": "Skin and Subcutaneous Tissue Disorders : Severe skin and hypersensitivity reactions including DRESS ( Drug Reaction with Eosinophilia and Systemic Symptoms ) .DRUG INTERACTIONS .", "label": "", "metadata": {}, "score": "63.743805"}
{"text": "Explanation of how the number of participants for analysis was determined .Includes whether analysis was per protocol , intention to treat , or another method .", "label": "", "metadata": {}, "score": "64.119354"}
{"text": "Explanation of how the number of participants for analysis was determined .Includes whether analysis was per protocol , intention to treat , or another method .", "label": "", "metadata": {}, "score": "64.119354"}
{"text": "Explanation of how the number of participants for analysis was determined .Includes whether analysis was per protocol , intention to treat , or another method .", "label": "", "metadata": {}, "score": "64.119354"}
{"text": "Participants in the Safety Analysis Set who had measurements for HDL cholesterol at both baseline and Week 24 were analyzed .Reporting Groups .Description .", "label": "", "metadata": {}, "score": "64.80542"}
{"text": "\u00a7 Includes subjects who discontinued for reasons other than an adverse event , death or lack or loss of efficacy , e.g. , withdrew consent , loss to follow - up , etc . .", "label": "", "metadata": {}, "score": "64.81813"}
{"text": "The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days .", "label": "", "metadata": {}, "score": "65.38118"}
{"text": "Liver enzyme monitoring should also be considered for patients without pre - existing hepatic dysfunction or other risk factors .Section 6 Adverse Reactions was updated with the Week 96 data from the phase 3 trials TMC278-C209 and TMC278-C215 .", "label": "", "metadata": {}, "score": "65.43282"}
{"text": "Storage And Handling .COMPLERA tablets are purplish - pink , capsule - shaped , film - coated , debossed with \" GSI \" on one side and plain - faced on the other side .", "label": "", "metadata": {}, "score": "65.469284"}
{"text": "[ 1 ] .FTC / RPV / TDF group : 110 participants completing the main study continued in extension phase .[ 2 ] .", "label": "", "metadata": {}, "score": "65.76976"}
{"text": "[ 1 ] .FTC / RPV / TDF group : 110 participants completing the main study continued in extension phase .[ 2 ] .", "label": "", "metadata": {}, "score": "65.76976"}
{"text": "Two - thirds started treatment with a viral load at or below 100,000 copies / mL , about 27 % had 100,000 to 500,000 copies / mL and about 7 % had above 500,000 copies / mL. Cohen reported results from a STaR sub - analysis looking at response rates according to baseline viral load and CD4 count .", "label": "", "metadata": {}, "score": "66.58482"}
{"text": "Subject Non - compliance .[ 1 ] .152 participants switched regimens at Week 24 .[ 2 ] .Discontinuations after switch : withdrawal by subject , 2 ; adverse event , 1 ; protocol violation , 1 .", "label": "", "metadata": {}, "score": "67.40274"}
{"text": "Subject Non - compliance .[ 1 ] .152 participants switched regimens at Week 24 .[ 2 ] .Discontinuations after switch : withdrawal by subject , 2 ; adverse event , 1 ; protocol violation , 1 .", "label": "", "metadata": {}, "score": "67.40274"}
{"text": "The information provided through The Body should not be used for diagnosing or treating a health problem or a disease .It is not a substitute for professional care .", "label": "", "metadata": {}, "score": "67.59883"}
{"text": "The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days .", "label": "", "metadata": {}, "score": "67.68793"}
{"text": "Response from Dr. Henry .The goal would be to find a convenient ( once or twice a day ) and well tolerated regimen for each person needing HIV treatment .", "label": "", "metadata": {}, "score": "68.512665"}
{"text": "Virological failure occurred in 8 % and 6 % , respectively , and CD4 gains were similar ( 200 vs 191 cells / mm 3 ) .", "label": "", "metadata": {}, "score": "71.98876"}
{"text": "Other Agents .Antacids : antacids ( e.g. , aluminum or magnesium hydroxide , calcium carbonate ) .The combination of EDURANT and antacids should be used with caution as co - administration may cause significant decreases in rilpivirine plasma concentrations ( increase in gastric pH ) .", "label": "", "metadata": {}, "score": "72.17052"}
{"text": "Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed .Restriction Description : .", "label": "", "metadata": {}, "score": "73.13099"}
{"text": "Patients had to have a pre - Atripla genotype showing no reverse transcriptase mutations .Estimated glomerular filtration rate had to be at or above 50 mL / min .", "label": "", "metadata": {}, "score": "73.41579"}
{"text": "Measured Values .Change From Baseline in Fasting High - density Lipoprotein ( HDL ) Cholesterol Through Week 24 [ units : mg / dL ] Mean ( Standard Deviation ) .", "label": "", "metadata": {}, "score": "73.43843"}
{"text": "Adrenal Function .In the pooled Phase 3 trials , at Week 96 , there was an overall mean change from baseline in basal cortisol of -19.1 ( -30.85 ; -7.37 ) nmol / L in the EDURANT group and of -0.6 ( -13.29 ; 12.17 ) nmol / L in the efavirenz group .", "label": "", "metadata": {}, "score": "74.138306"}
{"text": "The primary endpoint was a viral load below 50 copies 12 weeks after switching in an intention - to - treat analysis .Forty - five of 49 study participants ( 92 % ) were men , and 39 ( 80 % ) were white .", "label": "", "metadata": {}, "score": "74.791214"}
{"text": "Manufactured and distributed by : Gilead Sciences , Inc. , Foster City , CA 94404 .Revised : May 2015 .This monograph has been modified to include the generic and brand name in many instances .", "label": "", "metadata": {}, "score": "74.869865"}
{"text": "Interscience Conference on Antimicrobial Agents and Chemotherapy ( ICAAC ) .September 17 - 20 , 2011 .Chicago .Abstract H2 - 794c .Zheng J , Scourfield A , Waters L , et al .", "label": "", "metadata": {}, "score": "74.94809"}
{"text": "other boosted PIs ( atazanavir / ritonavir , fosamprenavir / ritonavir , saquinavir / ritonavir , tipranavir / ritonavir ) unboosted PIs ( atazanavir , fosamprenavir , indinavir , nelfinavir ) .", "label": "", "metadata": {}, "score": "76.51131"}
{"text": "Change From Baseline in Fasting High - density Lipoprotein ( HDL ) Cholesterol Through Week 24 .Measure Description .The mean ( SD ) change from baseline in fasting HDL cholesterol ( mg / dL ) through Week 24 was analyzed .", "label": "", "metadata": {}, "score": "77.07236"}
{"text": "The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract , manuscript , or presentation form ; or .", "label": "", "metadata": {}, "score": "77.982544"}
{"text": "Store at 25 \u00b0 C ( 77 \u00b0 F ) , excursions permitted to 15 \u00b0 C-30 \u00b0 C ( 59 \u00b0 F-86 \u00b0 F ) ( see USP Controlled Room Temperature ) .", "label": "", "metadata": {}, "score": "78.04895"}
{"text": "Experts appearing on this page are independent and are solely responsible for editing and fact - checking their material .The Body is a service of Remedy Health Media , LLC , 750 3rd Avenue , 6th Floor , New York , NY 10017 .", "label": "", "metadata": {}, "score": "78.16708"}
{"text": "51stInterscience Conference on Antimicrobial Agents and Chemotherapy ( ICAAC ) .September 17 - 20 , 2011 .Chicago .Abstract H2 - 783 .", "label": "", "metadata": {}, "score": "79.55407"}
{"text": "KH .This forum is designed for educational purposes only , and experts are not rendering medical , mental health , legal or other professional advice or services .", "label": "", "metadata": {}, "score": "79.83681"}
{"text": "General Disclaimer : The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services .The information provided through The Body should not be used for diagnosing or treating a health problem or a disease .", "label": "", "metadata": {}, "score": "82.747894"}
{"text": "Participants were enrolled at 110 sites in the North America and Europe .The first participant was screened on 17 November 2010 .The last participant observation was on 28 October 2014 .", "label": "", "metadata": {}, "score": "82.87181"}
{"text": "Participants were enrolled at 110 sites in the North America and Europe .The first participant was screened on 17 November 2010 .The last participant observation was on 28 October 2014 .", "label": "", "metadata": {}, "score": "82.87181"}
{"text": "You will now be able to tab or arrow up or down through the submenu options to access / activate the submenu links .Research Briefs .", "label": "", "metadata": {}, "score": "83.21002"}
{"text": "To access the menus on this page please perform the following steps .Please switch auto forms mode to off .Hit enter to expand a main menu option ( Health , Benefits , etc ) .", "label": "", "metadata": {}, "score": "83.749466"}
{"text": "Edurant .\"On March 20 , we recognize the impact of HIV / AIDS on American Indians , Alaska Natives and Native Hawaiians .This 7th national observance is our chance to raise awareness of the risks of HIV to Native people , to help communities understand what con \" ... .", "label": "", "metadata": {}, "score": "85.143936"}
{"text": "( Please note : Your name and comment will be public , and may even show up in Internet search results .Be careful when providing personal information !", "label": "", "metadata": {}, "score": "87.23982"}
{"text": "Please do not include either \" : \" or \" @ \" in your comment .The opinions expressed by people providing comments are theirs alone .", "label": "", "metadata": {}, "score": "88.723625"}
{"text": "If you have or suspect you may have a health problem , consult your health care provider .", "label": "", "metadata": {}, "score": "90.888504"}
{"text": "About 90 % were men , three - quarters were white , about 16 % were black , the median age was just over 40 years , and they had been on ART for nearly 3 years .", "label": "", "metadata": {}, "score": "93.04195"}
{"text": "The Body and its logos are trademarks of Remedy Health Media , LLC , and its subsidiaries , which owns the copyright of The Body 's homepage , topic pages , page designs and HTML code .", "label": "", "metadata": {}, "score": "94.06059"}
{"text": "The study included 786 participants .More than 90 % were men , about two - thirds were white , one - quarter were black , and the median age was 36 years .", "label": "", "metadata": {}, "score": "102.461914"}
